Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 62 of 151

  1. Gemcitabine

    Regeneron UK Limited

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  2. Gemcitabine , Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sarcoma

    phase 2 small molecule completed

    1 trial

  3. Gemcitabine 1000 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Phase II, Open-label, Parallel 2-arm, Multi-center

    phase 2 small molecule active

    1 trial

  4. Gemcitabine Oxaliplatin 5FU and Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  5. Gemcitabine plus Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  6. Gemcitabine+5FU+Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Disease

    phase 2 small molecule completed

    1 trial

  7. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  8. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  9. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  10. Genoxal polvo para solución inyectable y para...

    Autolus GmbH

    Relapsed or refractory B cell acute lymphoblastic leukaemia

    phase 2 small molecule active

    1 trial

  11. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  12. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  13. Gepirone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  14. Giapreza 2.5 mg/ml concentrate for solution for infusion

    Disc Medicine

    Liver cancer (primary or secondary)

    phase 2 small molecule active

    1 trial

  15. Gilteritinib

    Astellas Pharma Inc

    Non-Small-Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  16. Gimistotug

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. Giredestrant

    Hoffmann-La Roche

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Giredestrant

    Hoffmann-La Roche

    Early Breast Cancer

    phase 2 small molecule completed

    1 trial

  19. Givosiran

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 2 small molecule completed

    1 trial

  20. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  21. Glatiramer Acetate, N-Acetylcysteine

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  22. Gliolan 30 mg/ml powder for oral solution.

    Photonamic GmbH & Co. KG

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  23. Gliolan 30 mg/ml powder for oral solution.

    Photonamic GmbH & Co. KG

    Glioblastoma

    phase 2 small molecule active

    1 trial

  24. Glofitamab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory Aggressive B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  25. Glofitamab

    Peking University Third Hospital

    MCL

    phase 2 small molecule active

    1 trial

  26. Glofitamab for previously untreated aggressive B-cell lymphoma

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  27. Glucagon

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  28. Glucagon

    Universal Integrated

    Hypoglycemia Unawareness

    phase 2 small molecule terminated

    1 trial

  29. Glucagon

    Xeris Biopharma Holdings

    Congenital Hyperinsulinism

    phase 2 small molecule completed

    1 trial

  30. Glucagon RTU

    Xeris Biopharma Holdings

    Hyperinsulinemic Hypoglycemia

    phase 2 small molecule completed

    1 trial

  31. Glucagon RTU Injection With Insulin Pump Reduction

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  32. Glutamine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatic Heart Disease

    phase 2 small molecule completed

    1 trial

  33. Gluten- and casein-free diet

    United Therapeutics Europe Ltd

    Autism

    phase 2 other completed

    1 trial

  34. GlyT-1 inhibitor-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  35. Glycosides Of Tripterygium Wilfordii Hook(GTW)

    The First People's Hospital of Lianyungang

    Henoch-Schönlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  36. Glyoxalase 1 (Glo1) inducer

    United Therapeutics Europe Ltd

    Glucose Intolerance

    phase 2 other completed

    1 trial

  37. GnP in combination with Ivonescimab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  38. GnRHa/ hCG/ hMG

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Azoospermia

    phase 2 small molecule active

    1 trial

  39. Gocovri (extended-release amantidine)

    SUPERNUS PHARMACEUTICALS, INC.

    Radiation Encephalopathy

    phase 2 small molecule active

    1 trial

  40. Grafalon 20 mg/ml koncentrát pro infuzní roztok

    The George Institute

    Type 1 diabetes

    phase 2 small molecule active

    1 trial

  41. Granexin® gel (200 μM)

    United Therapeutics Europe Ltd

    Second Degree Burn

    phase 2 small molecule terminated

    1 trial

  42. Green Tea Polyphenols (EGCG/ECG)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  43. Green tea

    United Therapeutics Europe Ltd

    Lung Cancer Prevention

    phase 2 other completed

    1 trial

  44. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  45. Group A FMP2.1/AS01B

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  46. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  47. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 small molecule completed

    1 trial

  48. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.